MovDisordV3, PascalFrancis, Curation, bibRecord, 002B15

The Significance of Defining Preclinical or Prodromal Parkinson's Disease

Identifieur interne : 002B15 ( PascalFrancis/Curation ); précédent : 002B14; suivant : 002B16

The Significance of Defining Preclinical or Prodromal Parkinson's Disease

Auteurs : C. Warren Olanow [États-Unis] ; José A. Obeso [Espagne]

Source :

Movement disorders [ 0885-3185 ] ; 2012.

RBID : Pascal:12-0223373

Descripteurs français

Pascal (Inist)
- Maladie de Parkinson, Pathologie du système nerveux, Asymptomatique, Prodrome.

English descriptors

KwdEn :
- Asymptomatic, Nervous system diseases, Parkinson disease, Prodrome.

Abstract

A body of clinical and pathologic evidence supports the concept that there a pre-Parkinson state exists prior to the time when Parkinson's disease (PD) can be formally diagnosed. The ability to define a the preclinical or prodromal PD state has many important implications. First, understanding the timing and sequence of pathologic change that occurs in PD could provide important clues as to the etiology and pathogenesis of PD, and provide insight into cell vulnerability factors. Second, defining a population of patients with preclinical PD would provide a potentially important group of subjects for clinical trials attempting to define disease-modifying therapies. And, finally, being able to determine that a person has PD at an earlier time point than is currently possible would permit the introduction of a putative disease-modifying therapy at a time when it could have more profound and long-lasting effects. This paper reviews the clinical significance of defining preclinical PD.

A01	`01`	`1`		`@0 0885-3185`
A03		`1`		`@0 Mov. disord.`
A05				`@2 27`
A06				`@2 5`
A08	`01`	`1`	`ENG`	`@1 The Significance of Defining Preclinical or Prodromal Parkinson's Disease`
A09	`01`	`1`	`ENG`	`@1 Prodromal Parkinson's Disease`
A11	`01`	`1`		`@1 OLANOW (C. Warren)`
A11	`02`	`1`		`@1 OBESO (José A.)`
A12	`01`	`1`		`@1 BERG (Daniela) @9 ed.`
A12	`02`	`1`		`@1 POEWE (Werner) @9 ed.`
A14	`01`			`@1 Departments of Neurology and Neuroscience, Mount Sinai School of Medicine @2 New York, New York @3 USA @Z 1 aut.`
A14	`02`			`@1 Department of Neurology, University of Navarra @2 Pamplona @3 ESP @Z 2 aut.`
A15	`01`			`@1 Department of Neurodegeneration, Hertie Institute of Clinical Brain Research and German Center of Neurodegenerative Diseases (DZNE), University of Tübingen @2 Tübingen @3 DEU @Z 1 aut.`
A15	`02`			`@1 Department of Neurology, University of Innsbruck @2 Innsbruck @3 AUT @Z 2 aut.`
A20				`@1 666-669`
A21				`@1 2012`
A23	`01`			`@0 ENG`
A43	`01`			`@1 INIST @2 20953 @5 354000506918320090`
A44				`@0 0000 @1 © 2012 INIST-CNRS. All rights reserved.`
A45				`@0 28 ref.`
A47	`01`	`1`		`@0 12-0223373`
A60				`@1 P`
A61				`@0 A`
A64	`01`	`1`		`@0 Movement disorders`
A66	`01`			`@0 USA`
C01	`01`		`ENG`	@0 A body of clinical and pathologic evidence supports the concept that there a pre-Parkinson state exists prior to the time when Parkinson's disease (PD) can be formally diagnosed. The ability to define a the preclinical or prodromal PD state has many important implications. First, understanding the timing and sequence of pathologic change that occurs in PD could provide important clues as to the etiology and pathogenesis of PD, and provide insight into cell vulnerability factors. Second, defining a population of patients with preclinical PD would provide a potentially important group of subjects for clinical trials attempting to define disease-modifying therapies. And, finally, being able to determine that a person has PD at an earlier time point than is currently possible would permit the introduction of a putative disease-modifying therapy at a time when it could have more profound and long-lasting effects. This paper reviews the clinical significance of defining preclinical PD.
C02	`01`	`X`		`@0 002B17`
C02	`02`	`X`		`@0 002B17G`
C03	`01`	`X`	`FRE`	`@0 Maladie de Parkinson @2 NM @5 01`
C03	`01`	`X`	`ENG`	`@0 Parkinson disease @2 NM @5 01`
C03	`01`	`X`	`SPA`	`@0 Parkinson enfermedad @2 NM @5 01`
C03	`02`	`X`	`FRE`	`@0 Pathologie du système nerveux @5 02`
C03	`02`	`X`	`ENG`	`@0 Nervous system diseases @5 02`
C03	`02`	`X`	`SPA`	`@0 Sistema nervioso patología @5 02`
C03	`03`	`X`	`FRE`	`@0 Asymptomatique @5 09`
C03	`03`	`X`	`ENG`	`@0 Asymptomatic @5 09`
C03	`03`	`X`	`SPA`	`@0 Asintomático @5 09`
C03	`04`	`X`	`FRE`	`@0 Prodrome @4 CD @5 96`
C03	`04`	`X`	`ENG`	`@0 Prodrome @4 CD @5 96`
C03	`04`	`X`	`SPA`	`@0 Pródromo @4 CD @5 96`
C07	`01`	`X`	`FRE`	`@0 Pathologie de l'encéphale @5 37`
C07	`01`	`X`	`ENG`	`@0 Cerebral disorder @5 37`
C07	`01`	`X`	`SPA`	`@0 Encéfalo patología @5 37`
C07	`02`	`X`	`FRE`	`@0 Syndrome extrapyramidal @5 38`
C07	`02`	`X`	`ENG`	`@0 Extrapyramidal syndrome @5 38`
C07	`02`	`X`	`SPA`	`@0 Extrapiramidal síndrome @5 38`
C07	`03`	`X`	`FRE`	`@0 Maladie dégénérative @5 39`
C07	`03`	`X`	`ENG`	`@0 Degenerative disease @5 39`
C07	`03`	`X`	`SPA`	`@0 Enfermedad degenerativa @5 39`
C07	`04`	`X`	`FRE`	`@0 Pathologie du système nerveux central @5 40`
C07	`04`	`X`	`ENG`	`@0 Central nervous system disease @5 40`
C07	`04`	`X`	`SPA`	`@0 Sistema nervosio central patología @5 40`
N21				`@1 170`
N44	`01`			`@1 OTO`
N82				`@1 OTO`

Links toward previous steps (curation, corpus...)

to stream PascalFrancis, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000199

Links to Exploration step

Pascal:12-0223373

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">The Significance of Defining Preclinical or Prodromal Parkinson's Disease</title>
<author><name sortKey="Olanow, C Warren" sort="Olanow, C Warren" uniqKey="Olanow C" first="C. Warren" last="Olanow">C. Warren Olanow</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Departments of Neurology and Neuroscience, Mount Sinai School of Medicine</s1>
<s2>New York, New York</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Obeso, Jose A" sort="Obeso, Jose A" uniqKey="Obeso J" first="José A." last="Obeso">José A. Obeso</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Department of Neurology, University of Navarra</s1>
<s2>Pamplona</s2>
<s3>ESP</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>Espagne</country>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">12-0223373</idno>
<date when="2012">2012</date>
<idno type="stanalyst">PASCAL 12-0223373 INIST</idno>
<idno type="RBID">Pascal:12-0223373</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000199</idno>
<idno type="wicri:Area/PascalFrancis/Curation">002B15</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">The Significance of Defining Preclinical or Prodromal Parkinson's Disease</title>
<author><name sortKey="Olanow, C Warren" sort="Olanow, C Warren" uniqKey="Olanow C" first="C. Warren" last="Olanow">C. Warren Olanow</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Departments of Neurology and Neuroscience, Mount Sinai School of Medicine</s1>
<s2>New York, New York</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Obeso, Jose A" sort="Obeso, Jose A" uniqKey="Obeso J" first="José A." last="Obeso">José A. Obeso</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Department of Neurology, University of Navarra</s1>
<s2>Pamplona</s2>
<s3>ESP</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>Espagne</country>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
<imprint><date when="2012">2012</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Asymptomatic</term>
<term>Nervous system diseases</term>
<term>Parkinson disease</term>
<term>Prodrome</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Maladie de Parkinson</term>
<term>Pathologie du   système nerveux</term>
<term>Asymptomatique</term>
<term>Prodrome</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">A body of clinical and pathologic evidence supports the concept that there a pre-Parkinson state exists prior to the time when Parkinson's disease (PD) can be formally diagnosed. The ability to define a the preclinical or prodromal PD state has many important implications. First, understanding the timing and sequence of pathologic change that occurs in PD could provide important clues as to the etiology and pathogenesis of PD, and provide insight into cell vulnerability factors. Second, defining a population of patients with preclinical PD would provide a potentially important group of subjects for clinical trials attempting to define disease-modifying therapies. And, finally, being able to determine that a person has PD at an earlier time point than is currently possible would permit the introduction of a putative disease-modifying therapy at a time when it could have more profound and long-lasting effects. This paper reviews the clinical significance of defining preclinical PD.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0885-3185</s0>
</fA01>
<fA03 i2="1"><s0>Mov. disord.</s0>
</fA03>
<fA05><s2>27</s2>
</fA05>
<fA06><s2>5</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>The Significance of Defining Preclinical or Prodromal Parkinson's Disease</s1>
</fA08>
<fA09 i1="01" i2="1" l="ENG"><s1>Prodromal Parkinson's Disease</s1>
</fA09>
<fA11 i1="01" i2="1"><s1>OLANOW (C. Warren)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>OBESO (José A.)</s1>
</fA11>
<fA12 i1="01" i2="1"><s1>BERG (Daniela)</s1>
<s9>ed.</s9>
</fA12>
<fA12 i1="02" i2="1"><s1>POEWE (Werner)</s1>
<s9>ed.</s9>
</fA12>
<fA14 i1="01"><s1>Departments of Neurology and Neuroscience, Mount Sinai School of Medicine</s1>
<s2>New York, New York</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
</fA14>
<fA14 i1="02"><s1>Department of Neurology, University of Navarra</s1>
<s2>Pamplona</s2>
<s3>ESP</s3>
<sZ>2 aut.</sZ>
</fA14>
<fA15 i1="01"><s1>Department of Neurodegeneration, Hertie Institute of Clinical Brain Research and German Center of Neurodegenerative Diseases (DZNE), University of Tübingen</s1>
<s2>Tübingen</s2>
<s3>DEU</s3>
<sZ>1 aut.</sZ>
</fA15>
<fA15 i1="02"><s1>Department of Neurology, University of Innsbruck</s1>
<s2>Innsbruck</s2>
<s3>AUT</s3>
<sZ>2 aut.</sZ>
</fA15>
<fA20><s1>666-669</s1>
</fA20>
<fA21><s1>2012</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>20953</s2>
<s5>354000506918320090</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2012 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>28 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>12-0223373</s0>
</fA47>
<fA60><s1>P</s1>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Movement disorders</s0>
</fA64>
<fA66 i1="01"><s0>USA</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>A body of clinical and pathologic evidence supports the concept that there a pre-Parkinson state exists prior to the time when Parkinson's disease (PD) can be formally diagnosed. The ability to define a the preclinical or prodromal PD state has many important implications. First, understanding the timing and sequence of pathologic change that occurs in PD could provide important clues as to the etiology and pathogenesis of PD, and provide insight into cell vulnerability factors. Second, defining a population of patients with preclinical PD would provide a potentially important group of subjects for clinical trials attempting to define disease-modifying therapies. And, finally, being able to determine that a person has PD at an earlier time point than is currently possible would permit the introduction of a putative disease-modifying therapy at a time when it could have more profound and long-lasting effects. This paper reviews the clinical significance of defining preclinical PD.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002B17</s0>
</fC02>
<fC02 i1="02" i2="X"><s0>002B17G</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Maladie de Parkinson</s0>
<s2>NM</s2>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Parkinson disease</s0>
<s2>NM</s2>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Parkinson enfermedad</s0>
<s2>NM</s2>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Pathologie du   système nerveux</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Nervous system diseases</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Sistema nervioso patología</s0>
<s5>02</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Asymptomatique</s0>
<s5>09</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Asymptomatic</s0>
<s5>09</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Asintomático</s0>
<s5>09</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Prodrome</s0>
<s4>CD</s4>
<s5>96</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Prodrome</s0>
<s4>CD</s4>
<s5>96</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Pródromo</s0>
<s4>CD</s4>
<s5>96</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Pathologie de l'encéphale</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Cerebral disorder</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Encéfalo patología</s0>
<s5>37</s5>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Syndrome extrapyramidal</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Extrapyramidal syndrome</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Extrapiramidal síndrome</s0>
<s5>38</s5>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Maladie dégénérative</s0>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Degenerative disease</s0>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Enfermedad degenerativa</s0>
<s5>39</s5>
</fC07>
<fC07 i1="04" i2="X" l="FRE"><s0>Pathologie du   système nerveux central</s0>
<s5>40</s5>
</fC07>
<fC07 i1="04" i2="X" l="ENG"><s0>Central nervous system disease</s0>
<s5>40</s5>
</fC07>
<fC07 i1="04" i2="X" l="SPA"><s0>Sistema nervosio central patología</s0>
<s5>40</s5>
</fC07>
<fN21><s1>170</s1>
</fN21>
<fN44 i1="01"><s1>OTO</s1>
</fN44>
<fN82><s1>OTO</s1>
</fN82>
</pA>
</standard>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/PascalFrancis/Curation

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002B15 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Curation/biblio.hfd -nk 002B15 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    PascalFrancis
   |étape=   Curation
   |type=    RBID
   |clé=     Pascal:12-0223373
   |texte=   The Significance of Defining Preclinical or Prodromal Parkinson's Disease
}}

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024

	Movement Disorders (revue)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Movement Disorders (revue)

The Significance of Defining Preclinical or Prodromal Parkinson's Disease

The Significance of Defining Preclinical or Prodromal Parkinson's Disease

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri